ImmunityBio Inc

IBRX

Company Profile

  • Business description

    ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

  • Contact

    3530 John Hopkins Court
    San DiegoCA92121
    USA

    T: +1 844 696-5235

    https://www.immunitybio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    691

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,251.90100.10-1.20%
DAX 4026,201.81396.83-1.49%
Dow JONES (US)51,195.77412.40-0.80%
FTSE 10010,745.41136.14-1.25%
HKSE23,508.17245.67-1.03%
NASDAQ24,414.1495.62-0.39%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,383.4833.11-0.45%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers